Main description:

Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.

Contents:

Foreword Juliet Compston

Preface

Chapter 1 Osteoporosis: Pathophysiology & Epidemiology

Rebecca J. Moon, Cyrus Cooper, and Nicholas C. Harvey

Chapter 2 Antiresorptives

R. Graham G. Russell, Maria K. Tsoumpra, Frank H. Ebetino, Michael Pazianas

Chapter 3 Anabolics

Erik Fink Eriksen

Chapter 4 Tools for Assessing Fracture Risk and for Treatment Monitoring

William D. Leslie, Lisa M. Lix, and Suzanne N. Morin

Chapter 5 Treatment Failure

Elisa Torres del Pliego, Daniel Prieto-Alhambra, and Adolfo Diez-Perez

Chapter 6 Epidemiology of Atypical Subtrochanteric and Femoral Shaft Fractures

Jeri W. Nieves

Chapter 7 Bisphosphonate-Related Atypical Femoral Fractures and Their Radiographic Features

Joseph C. Giaconi and C. Travis Watterson

Chapter 8 Factors Contributing to Atypical Femoral Fractures

Adele L. Boskey and Marjolein C. H. van der Meulen

Chapter 9 Clinical Presentation of Atypical Femur Fractures

Yelena Bogdan and Thomas A. Einhorn

Chapter 10 Effects of Antiresorptive Therapy on Bone Microarchitecture

Joy N. T

sai and Mary L. Bouxsein

Chapter 11 Management of Atypical Femoral Fractures

Joseph M. Lane, Libi Z. Galmer, David S. Wellman, Abigail L. Campbell, Jonathan E. Jo

Chapter 12 Osteonecrosis of the Jaw: Clinico-Pathologic and Radiologic Features

Parish P. Sedghizadeh and Allan C. Jones

Chapter 13 Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment

Morten Schiodt

Chapter 14 Management of Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Treatment

Morten Schiodt

Chapter 15 Long-Term Efficacy and Safety of Treatments for Osteoporosis

Socrates E. Papapoulos

Chapter 16 Management of Drug Holidays

Christian Roux and Karine Briot

Chapter 17 Patients Who Do Not Take Their Osteoporosis Medications: Can We Help Them Become Compliant?

Deborah T. Gold

Chapter 18 Fractures and Healing on Antiresorptive Therapy

Eli Kupperman and Susan V. Bukata

Chapter 19 Antiresorptive Therapy and Mortality and Cancer Incidence

Peter Vestergaard

Chapter 20 Other Safety Concerns

Michael R. McClung

Chapter 21 The Impact of Regulatory and Scientific Organizations Recommendations on Clinical Decision Making

Alexandra Papaioannou, Arnav Agarwal, and Sarah Karampatos

Chapter 22 Integrated Clinical View on Long-Term Management of Patients with Osteoporosis

E. Michael Lewiecki

Chapter 23 Conclusions

Stuart L. Silverman and Bo Abrahamsen